During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
MedPage Today on MSN10d
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBCUse of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
In the post hoc analysis, the benefit of adjuvant nivolumab was seen both in patients with MIBC who had previously received neoadjuvant chemotherapy and those who had not, and in patients with ...
PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...
Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback